(2012) 12:173–80. doi:10.1007/s10238-011-0159-0 40. Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Personali zed approachestoactiveimmunotherapyincancer. BiochimBiophysActa. (2016) 1865:72–82.doi:10.1016/j.bbcan.2015.07.004 41. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S , Biankin AV,etal.Signaturesofmutationalprocessesinhumancancer. Nature.(2013) 500:415–21.doi:10.1038/nature12477 42. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Siv achenko A, et al. Mutational heterogeneity in cancer and the search for new cancer- associatedgenes. Nature.(2013)499:214–8.doi:10.1038/nature12213 43. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science.(2013) 339:1546–58. doi:10.1126/science.1235122 44. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-speciﬁc T-cell reac tivity in an ipilimumab-responsive melanoma. J Clin Oncol. (2013) 31:e439–42. doi:10.1200/JCO.2012.47.7521 45. SnyderA,MakarovV,MerghoubT,YuanJ,ZaretskyJM,Desrich ardA,etal. GeneticbasisforclinicalresponsetoCTLA-4blockadeinmelanoma. NEngl JMed.(2014)371:2189–99.doi:10.1056/NEJMoa1406498 46. Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, et al. Mutat ional proﬁling of colorectal cancers with microsatellite instability. Oncotarget. (2015)6:42334–44.doi:10.18632/oncotarget.5997 47. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel J J, et al. Cancer immunobiology. mutational landscape determines sensit ivity to PD-1 blockade in non-small cell lung cancer. Science.(2015) 348:124–8.